-

Channel Medsystems Brings Women New, Minimally Invasive Alternative Treatment with AcuityAI

AcuityMD enables successful re-launch of Cerene Endometrial Cryotherapy platform to provide a better option for the 1 in 5 women suffering from heavy bleeding and dysmenorrhea

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform trusted by over 500 MedTech companies, today announced its partnership with Channel Medsystems, a medical technology (medtech) company dedicated to transforming women’s healthcare globally to commercially relaunch Cerene Endometrial Cryotherapy. Cerene is a non-hormonal, incision-free endometrial cryotherapy treatment designed to reduce heavy menstrual bleeding (menorrhagia), which affects one in five or 10 million women in the U.S.

Channel Medsystems implemented a new, data-driven commercial strategy with AcuityAI and quickly experienced sizable increases in new accounts, re-order rates, and quarter-over-quarter growth.

Share

Despite developing a minimally invasive, in-office treatment for heavy menstrual bleeding and dysmenorrhea, Channel Medsystems faced surprisingly low engagement among targeted physicians at launch. The company re-analyzed market data and discovered it was targeting the wrong group of healthcare providers, doctors focused strictly on treating the condition with heat-based ablation therapy. Channel Medsystems endometrial cryotherapy was being incorrectly compared to the 25-year-old ablation approach, with a declining user base. Channel Medsystems leveraged AcuityAI to successfully pivot its commercial strategy and relaunch Cerene.

“We scrubbed the word ‘ablation’ from everything, and completely rebranded all commercial materials to focus strictly on the differentiators and advantages of cryotherapy. It’s a different technology that preserves access to the uterine cavity,” explained Tara Murphy, Channel Medsystems Vice President of Marketing. “And we leaned into AcuityAI to help us identify the right target physicians, prioritize markets with the largest opportunity, and strategically expand our field team with better customer segmentation.”

Channel Medsystems implemented the new, data-driven commercial strategy and quickly experienced sizable increases in new accounts, re-order rates, and quarter over quarter growth.

“Since relaunching Cerene using AcuityMD’s AI platform to develop a refreshed customer segmentation strategy, we have made meaningful progress increasing physician engagement and building awareness of a differentiated treatment option for women suffering from heavy menstrual bleeding and dysmenorrhea,” added Murphy. “Our progress continues with AcuityMD’s Salesforce integration as we can easily import target lists into Salesforce as leads.”

Notably, with the addition of prescription data in AcuityAI, Channel Medsystems will now be able to find a subset of women suffering with heavy periods who are prescribed birth control as a treatment yet both the patients and their prescribers may not be aware of Channel Medsystems’ non-hormonal treatment option. With AcuityAI, the company can quickly see who is prescribing birth control and begin to understand if they are a potential Cerene candidate.

Channel Medsystems has also partially credited AcuityAI data for recent funding as it leveraged the solution to demonstrate its commercial pathway to investors. And, as a result, the company announced it reached $30 million in its ongoing Series C funding in August 2026. “AcuityMD provided the right data to validate and back our claims to investors and instill confidence for our future success,” concluded Murphy. “We showed investors that we are making decisions guided by industry-specific data, and that all came from AcuityMD.”

Learn about how AcuityMD is empowering MedTech organizations like Channel Medsystems at HLTH 2026 in Las Vegas. Join AcuityMD on Tuesday, Nov 17 at 1:50 pm at the Insights Stage, where executives will discuss how to drive innovations to patients faster using AI.

About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide a safe, effective and convenient therapy for women suffering from heavy menstrual bleeding without the need for general anesthesia. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access and empowering women with greater control over their care. For more information, please visit Cerene.com.

About AcuityMD
AcuityMD is the AI platform for MedTech trusted by over 500 MedTech companies – including 16 of the top 20. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413 | lbarbadora@barbadoraink.com

AcuityMD


Release Versions

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for AcuityMD
+1 (610) 420-3413 | lbarbadora@barbadoraink.com

Social Media Profiles
More News From AcuityMD

AcuityMD Brings Early Signals to AcuityAI, Helping MedTech Sales Teams Spot Changes in Physician Activity Sooner

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced the availability of Early Signals in AcuityAI, giving commercial teams earlier visibility into potential changes in healthcare provider (HCP) procedure activity. Drawing on recent medical claims data, AcuityAI can identify early indicators that a physician may have started performing a procedure they had not performed previously. This intelligence also helps sales reps target new physicians and engage them ahead of...

AcuityAI Now Includes Health Network Data to Help MedTech Teams Uncover Opportunities Across Entire Health Systems

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced the availability of health network intelligence in AcuityAI, giving MedTech commercial teams a comprehensive view of healthcare sites, sales performance, and opportunities across health systems and purchasing networks. Sales teams can ask AcuityAI about integrated delivery networks (IDNs), group purchasing organizations (GPOs), regional purchasing coalitions (RPCs), and management services organizations (MSOs) and g...

AcuityMD Launches AcuityAI Artifacts to Turn Chat Insights Into Structured, Shareable Outputs

BOSTON--(BUSINESS WIRE)--AcuityMD, the AI platform for MedTech, today announced AcuityAI Artifacts, a new capability that transforms AI-generated insights into structured, reusable content for commercial teams. With Artifacts, users can turn AcuityAI conversations into call plans, market analyses, account comparisons, targeting lists, and reports that can be easily saved, refined, and exported. Artifacts ensure valuable insights extend beyond a single conversation, enabling teams to continuousl...
Back to Newsroom